Helminthic therapy and restless legs syndrome (RLS)
Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a common, chronic movement disorder in which patients experience an irresistible urge to move their legs, usually combined with uncomfortable or unpleasant sensations. These symptoms, which occur or worsen during rest, usually in the evening and at night, disappear with movement of the legs.
RLS may arise spontaneously or can be secondary to conditions such as renal disease and polyneuropathy. A number of variants of several genes have been associated with RLS risk, [1] and the condition has been linked with inflammation.
RLS is associated with inflammation[edit | edit source]
Numerous doctors have observed a correlation between RLS and inflammation.

(Dr. Leonard Weinstock, MD, Certified in Internal Medicine and Gastroenterology, St. Louis, MO)

(Dr. Arthur Walters, MD, Professor of Neurology, Vanderbilt Department of Neurology)

(Dr. Giulio Romano, MD, Professor of Nephrology, University of Udine, Italy)

(Dr. Michael Cutler, MD, Family Physician, Salinas, CA)
RLS appears frequently in patients with inflammatory bowel disease, [2] and it is one of the most frequent comorbidities accompanying the autoimmune disease, multiple sclerosis. [3]
The following papers further demonstrate the link with inflammation.
- Severe recurrent restless legs syndrome associated with systemic inflammation
- Circulating levels of cytokines are increased in restless legs syndrome
- Restless legs syndrome - Theoretical roles of inflammatory and immune mechanisms -- PDF
- Association between the neutrophil-to-lymphocyte ratio, a new marker of systemic inflammation, and restless legs syndrome -- Full text | PDF
The history of RLS suggests a solution[edit | edit source]
Although isolated descriptions of RLS began to appear in the latter part of the 17th century, a detailed clinical description was only published in the mid-twentieth century, eventually leading to RLS becoming a well-recognised clinical entity that is now estimated to affect between 5 and 15 percent of US adults and 2 to 4 percent of children, with more than three million new cases appearing each year. [4]
As with many other inflammatory conditions, the incidence of RLS appears to have increased alongside industrialisation, suggesting that it may be one of many conditions the incidence of which has increased in line with the gradual loss of intestinal worms in industrialised societies from the mid 19th century onwards. This loss has created an evolutionary mismatch that has left humans bereft of the powerful inflammation control with which worms have provided our species for millennia, and without which our immune systems are free to attack our own tissues. For more about these inflammation-associated deficiencies in immune function, see Humans need helminths and The rewards of re-worming.
There have been no clinical trials of helminthic therapy in RLS, and it is unlikely there will be any in the forseeable future because living worms cannot be patented, so there is no incentive for anyone to put up the millions of dollars that would be required to mount a trial.
Therapeutic helminths shown to be effective in RLS[edit | edit source]
This first report is more detailed than the quotes that follow.
Several other individuals have reported the successful resoltion of their RLS as a result of hosting therapeutic helminths.






